Drugs of Today
| 短名 | Drugs Today |
| Journal Impact | 1.67 |
| 国际分区 | PHARMACOLOGY & PHARMACY(Q4) |
| 期刊索引 | SCI Q4中科院 4 区 |
| ISSN | 1699-3993, 1699-4019 |
| h-index | 57 |
| 国内分区 | 医学(4区)医学药学(4区) |
一本国际同行评审期刊，出版关于进入市场的新产品和评论文章的专着。自 1965 年成立以来，今日药物在为医生和其他主要医疗保健专业人员提供实用的最新技术方面建立了卓越的声誉最近批准和上市的药物专着。
期刊主页投稿网址| 涉及主题 | 医学生物内科学遗传学病理化学药理学生物化学心理学免疫学精神科内分泌学外科生物信息学 |
| 出版信息 | 出版商: Clarivate，出版周期: Monthly，期刊类型: journal |
| 基本数据 | 创刊年份: 1978，原创研究文献占比: 82.98%，自引率:N.A.， Gold OA占比: 0.00% |
| 平均审稿周期 | 网友分享经验：较慢,6-12周 |
| 平均录用比例 | 网友分享经验：容易 |
期刊引文格式
这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Cenegermin for the treatment of dry eye disease
2023-3-1
Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer
2023-3-1
Mitapivat for sickle cell disease and thalassemia
2023-3-1
Tebentafusp: A novel drug for the treatment of metastatic uveal melanoma
2023-3-1
New product intros (adagrasib, dengue tetravalent vaccine (live, attenuated), lecanemab, olutasidenib, RBX-2660 (first-in-class), teclistamab, teplizumab (first-in-class), toludesvenlafaxine hydrochloride, ublituximab)
2023-3-1
Anakinra as a potential treatment for COVID-19
2023-3-1
Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis
2023-3-1
Monoclonal antibodies for treatment of osteoporosis
2023-3-1
Donafenib in hepatocellular carcinoma
2023-2-1
Atidarsagene autotemcel for metachromatic leukodystrophy
2023-2-1
Anifrolumab in systemic lupus erythematosus
2023-2-1
Clascoterone for treatment of acne
2023-2-1
Nivolumab and relatlimab for the treatment of melanoma
2023-2-1
New product intros [ezetimibe/pitavastatin (new combination), ozoralizumab, ripasudil/brimonidine (new combination), spesolimab, valemetostat tosylate (first-in-class), valoctocogene roxaparvovec]
2023-1-1
Lutetium Lu 177 vipivotide tetraxetan for prostate cancer
2023-1-1
Savolitinib for non-small cell lung cancer
2023-1-1
The 2022 TOPRA Annual Symposium - Medical Device and IVD Symposium (October 17-19, 2022 - Vienna, Austria)
2023-1-1
Ciltacabtagene autoleucel for the treatment of multiple myeloma
2023-1-1
Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection
2022-12-1
COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues
2022-12-1
New product intros
2022-12-1
Current treatment options for treating OPA1-mutant dominant optic atrophy
2022-11-1
New product intros
2022-11-1
Olverembatinib in chronic myeloid leukemia
2022-11-1
Mobocertinib in non-small cell lung cancer
2022-11-1
Optimizing the use of Paxlovid in clinical practice
2022-11-1
Somapacitan: a long-acting growth hormone derivative for treatment of growth hormone deficiency
2022-10-1
Disitamab vedotin, a novel HER2-directed antibody–drug conjugate in gastric cancer and other solid tumors
2022-10-1
New product intros
2022-10-1
Aducanumab for the treatment of Alzheimer's disease
2022-10-1
Asciminib in chronic myeloid leukemia
2022-10-1
New product intros
2022-9-1
Melphalan flufenamide for relapsed/refractory multiple myeloma
2022-8-1
New product intros
2022-8-1
Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer
2022-8-1
Abrocitinib in atopic dermatitis: review of the current literature and clinical trials
2022-8-1
Atogepant for migraine
2022-8-1
New product intros
2022-7-1
Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer
2022-6-1
New product intros
2022-6-1
Asparaginase Erwinia chrysanthemi for acute lymphoblastic leukemia and lymphoblastic lymphoma
2022-6-1
Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma
2022-6-1
Bimekizumab for psoriasis
2022-6-1
Drug Information Association (DIA) Europe - 34th Annual Meeting (March 29-31, 2022 - Brussels, Belgium/Virtual)
2022-5-1
Efficacy, safety and cost of gene therapy medicinal products in the U.S. and Europe
2022-5-1
Belumosudil for chronic graft-versus-host disease
2022-5-1
Fluticasone propionate as a potential treatment for COVID-19
2022-5-1
New product intros [ansuvimab; benzoyl peroxide/tretinoin (new combination); faricimab; gallium (68Ga) gozetotide, kit for preparation; leuprolide mesylate; lutetium (177Lu) vipivotide tetraxetan; SARS-CoV-2 recombinant spike protein nanoparticle vaccine]
2022-5-1
Tisotumab vedotin for the treatment of cervical carcinoma
2022-5-1
Tanezumab for the treatment of osteoarthritis pain
2022-4-1
帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理
投稿经验分享
分享我的经验，帮你走得更远